RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MILELLA M
Collezione ASL Cuneo 2

Items : 4

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2024 Apr 18;73(6):106. doi: 10.1007/s00262-024-03682-w.

2024
ASL Cuneo 2
AOU Novara

Mosca A; Morelli F; Bisonni R; Bamias A; Santini D; Herchhorn D; Kanesvaran R; Inman E; Caitano M; Messina C; Martignetti A; Kopecky J; Milella M; Procopio G; Abahssain H; Roviello G; Kopp RM; Bassanelli M; Fernandez M; Cutuli HJ; Grillone F; Aceituno LG; Seront E; de Carvalho Fernandes R; Nogueira L; Mennitto A; Dauster B; Monteiro FSM; Barillas A; et alii...

Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study. in Frontiers in oncology / Front Oncol. 2024 Feb 12;14:1307635. doi: 10.3389/fonc.2024.1307635. eCollection 2024.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Roviello G; Lipari H; Cavo A; Vignani F; Nolè F; Prati G; Morelli F; Spada M; Caffo O; Di Napoli M; Atzori F; Malgeri A; Prati V; Sorarù M; Tudini M; Mollica V; Ricotta R; Baldessari C; Fratino L; Milella M; Procopio G; Naglieri E; Masini C; Zucali PA; Galli L; Chiellino S; Bimbatti D; De Giorgi U; Rebuzzi SE; et alii...

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study. in Journal of translational medicine / J Transl Med. 2022 Sep 30;20(1):435. doi: 10.1186/s12967-022-03601-6.

2022
ASL Cuneo 2
AO Ordine Mauriziano

Messina M; Caffo O; Di Napoli M; Atzori F; Santini D; Soto Parra HJ; Prati V; Cortellini A; Santoni M; Sorarù M; Mollica V; Panni S; Ricotta R; Pipitone S; Fratino L; Boccardo F; Milella M; Procopio G; Naglieri E; Fantinel E; Zucali PA; Galli L; Chiellino S; Basso U; De Giorgi U; Maruzzo M; Damassi A; Fornarini G; Gandini A; et alii...

The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The ?-Meet-URO analysis. in Frontiers in oncology / Front Oncol. 2022 Sep 23;12:955501. doi: 10.3389/fonc.2022.955501. eCollection 2022.

2022
ASL Cuneo 2
AO Ordine Mauriziano

Nolè F; Prati G; Morelli F; Messina M; Caffo O; Di Napoli M; Atzori F; Soto Parra HJ; Prati V; Cortellini A; Sorarù M; Santoni M; Massari F; Panni S; Ricotta R; Sabbatini R; Fratino L; Boccardo F; Milella M; Procopio G; Carella C; Fantinel E; Zucali PA; Galli L; Pedrazzoli P; De Giorgi U; Maruzzo M; Santini D; Stellato M; et alii...